Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.3.9824.5254
Address
Level 3 62 Lygon Street Carlton, Victoria (VIC) 3053
Description
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.06 - 0.17
Trade Value (12mth)
AU$13,192.00
1 week
-7%
1 month
-5.1%
YTD
20.78%
1 year
22.37%
All time high
15.60
EPS 3 yr Growth
-19.80%
EBITDA Margin
0.00%
Operating Cashflow
-$6m
Free Cash Flow Return
0.00%
ROIC
0.00%
Interest Coverage
0.00
Quick Ratio
4.90
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Healthcare
Next Company Report Date
29-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
05 September 24 |
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
×
Immuron Plans Phase 2 Trial for IMM-529 following FDA review |
30 August 24 |
Appendix 4E and Preliminary Final Report
×
Appendix 4E and Preliminary Final Report |
21 August 24 |
Immuron CEO presentation to Peak Biotech Showcase
×
Immuron CEO presentation to Peak Biotech Showcase |
16 August 24 |
New US DoD Research Award to develop enhanced Travelan
×
New US DoD Research Award to develop enhanced Travelan |
08 August 24 |
Immuron CEO presentation to MarketOpen Direct Connect
×
Immuron CEO presentation to MarketOpen Direct Connect |
07 August 24 |
Immuron CEO to host webinar on MarketOpen Direct Connect
×
Immuron CEO to host webinar on MarketOpen Direct Connect |
06 August 24 |
Change in substantial holding
×
Change in substantial holding |
31 July 24 |
Immuron CEO to present at TechKnow Invest Roadshow
×
Immuron CEO to present at TechKnow Invest Roadshow |
18 July 24 |
Immuron CEO to present at Emerging Growth Conference
×
Immuron CEO to present at Emerging Growth Conference |
16 July 24 |
Notification of cessation of securities - IMC
×
Notification of cessation of securities - IMC |
15 July 24 |
Immuron Travelan record sales globally, Australia and USA
×
Immuron Travelan record sales globally, Australia and USA |
09 July 24 |
Immuron CEO Steven Lydeamore presentation to Sharewise
×
Immuron CEO Steven Lydeamore presentation to Sharewise |
04 July 24 |
Immuron CEO Steven Lydeamore to present at Sharewise
×
Immuron CEO Steven Lydeamore to present at Sharewise |
03 July 24 |
Immuron lodges Form F-3 and ATM Prospectus with U.S. SEC
×
Immuron lodges Form F-3 and ATM Prospectus with U.S. SEC |
02 July 24 |
IMM-529 pre-IND FDA filing
×
IMM-529 pre-IND FDA filing |
05 June 24 |
Final Director's Interest Notice RA
×
Final Director's Interest Notice RA |
05 June 24 |
Initial Director's Interest Notice JJ
×
Initial Director's Interest Notice JJ |
31 May 24 |
Immuron CEO Steven Lydeamore to present at Peak Sky High
×
Immuron CEO Steven Lydeamore to present at Peak Sky High |
31 May 24 |
Board Changes
×
Board Changes |
24 May 24 |
Notification of cessation of securities - IMC
×
Notification of cessation of securities - IMC |
03 May 24 |
Board Change
×
Board Change |
03 May 24 |
Final Director's Interest Notice (SA)
×
Final Director's Interest Notice (SA) |
30 April 24 |
Change in substantial holding
×
Change in substantial holding |
23 April 24 |
Immuron CEO Steven Lydeamore to present at The Watchlist
×
Immuron CEO Steven Lydeamore to present at The Watchlist |
15 April 24 |
Immuron to host Live Virtual Event
×
Immuron to host Live Virtual Event |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.